دورية أكاديمية
Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose
| العنوان: | Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose |
|---|---|
| المؤلفون: | Tan, TM, Salem, V, Troke, RC, Alsafi, A, Field, BCT, De Silva, A, Misra, S, Baynes, KCR, Donaldson, M, Minnion, J, Ghatei, MA, Godsland, IF, Bloom, SR |
| المساهمون: | Medical Research Council (MRC) |
| المصدر: | E2324 ; E2317 |
| بيانات النشر: | Endocrine Society |
| سنة النشر: | 2014 |
| المجموعة: | Imperial College London: Spiral |
| مصطلحات موضوعية: | Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, BARIATRIC SURGERY, NEUROPEPTIDE-Y, FOOD-INTAKE, GASTRIC BYPASS, CELL FUNCTION, PYY3-36, SENSITIVITY, MORTALITY, APPETITE, RELEASE, Adult, Blood Glucose, Female, Glucagon-Like Peptide 1, Glucose, Glucose Tolerance Test, Homeostasis, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Obesity, Overweight, Peptide Fragments, Peptide YY, Young Adult |
| الوصف: | Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide, on glucose homeostasis are unknown. Objective: This study sought to investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity. Setting and Design: Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY3–36 alone, GLP-17–36 amide alone, and a combination of PYY3–36 and GLP-17–36 amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. Results: PYY3–36 alone caused a small but nonsignificant increase in AIRg. GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. Conclusions: PYY3–36 lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY3–36 and GLP-17–36 amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0021-972X |
| العلاقة: | Journal of Clinical Endocrinology and Metabolism; http://hdl.handle.net/10044/1/18802Test; G0701371; MR/J010936/1; G7811974; MR/K02115X/1; MR/J010731/1; G0802390; G1000474 |
| DOI: | 10.1210/jc.2014-2143 |
| الإتاحة: | https://doi.org/10.1210/jc.2014-2143Test http://hdl.handle.net/10044/1/18802Test |
| حقوق: | © 2014 The Authors. Copyright for this article is retained by the author(s). Author(s) grant(s) the Endocrine Society the exclusive right to publish the article and identify itself as the original publisher.This article has been published under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s). Author(s) grant(s) the Endocrine Society the exclusive right to publish the article and identify itself as the original publisher. ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.15977BD |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 0021972X |
|---|---|
| DOI: | 10.1210/jc.2014-2143 |